GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » PURE Bioscience Inc (OTCPK:PURE) » Definitions » Capex-to-Operating-Cash-Flow

PURE Bioscience (PURE Bioscience) Capex-to-Operating-Cash-Flow : 0.00 (As of Jan. 2024)


View and export this data going back to 1996. Start your Free Trial

What is PURE Bioscience Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

PURE Bioscience's Capital Expenditure for the three months ended in Jan. 2024 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Jan. 2024 was $-0.88 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


PURE Bioscience Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for PURE Bioscience's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PURE Bioscience Capex-to-Operating-Cash-Flow Chart

PURE Bioscience Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.09 - - -

PURE Bioscience Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PURE Bioscience's Capex-to-Operating-Cash-Flow

For the Household & Personal Products subindustry, PURE Bioscience's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PURE Bioscience's Capex-to-Operating-Cash-Flow Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, PURE Bioscience's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where PURE Bioscience's Capex-to-Operating-Cash-Flow falls into.



PURE Bioscience Capex-to-Operating-Cash-Flow Calculation

PURE Bioscience's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Jul. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.033) / -3.278
=N/A

PURE Bioscience's Capex-to-Operating-Cash-Flow for the quarter that ended in Jan. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.883
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PURE Bioscience  (OTCPK:PURE) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


PURE Bioscience Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of PURE Bioscience's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


PURE Bioscience (PURE Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
771 Jamacha Road, No. 512, El Cajon, CA, USA, 92019
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, products preserved with SDC and SDC as a raw material ingredient for manufacturing use.
Executives
Robert F Bartlett director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Bernard Blotner director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Tom Y Lee director 1807 SAN GABRIEL BLVD., SAN GABRIEL CA 91776
David Rendall director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Kristin Taylor director 13500 EVENING CREEK DRIVE N, SUITE 550, SAN DIEGO CA 92128
Dale Okuno director 35 N. ARROYO PARKWAY, SUITE 1, PASADENA CA 91103
Ivan Chen director 1725 GILLESPIE WAY, EL CAJON CA 92020
Thomas Richard Myers officer: Chief Operating Officer 1725 GILLESPIE WAY, EL CAJON CA 92130
Henry R. Lambert director, officer: Chief Executive Officer 1725 GILLESPIE WAY, EL CAJON CA 92020
Elisabeth Hagen director 1725 GILLESPIE WAY, EL CAJON CA 92020
Janet Risi Field director 9200 SOUTH DADELAND BOULEVARD, SUITE 800, MIAMI FL 33156
Franchise Brands, Llc 10 percent owner 325 BIC DRIVE, MILFORD CT 06461
Mark Stuart Elliott officer: Vice President, Finance 1725 GILLESPIE WAY, EL CAJON CA 92020
William Otis director 1725 GILLESPIE WAY, EL CAJON CA 92020
David M Theno director 1725 GILLESPIE WAY, EL CAJON CA 92020